Nurix Therapeutics, Inc. (Nasdaq: NRIX) has earned a $10 million milestone payment following a key development in its collaboration with Sanofi. The payment was triggered by the initiation of the Phase 1 first-in-human clinical trial for SAR448272/NX-3911, an oral STAT6 degrader, marking a significant progression in the drug's development pipeline.

The milestone underscores the advancing clinical status of the compound, which is being developed through the partnership between Nurix and Sanofi. Nurix Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines. The initiation of the trial represents a critical step in evaluating the safety and efficacy of the oral STAT6 degrader in human subjects.

Trial Initiation Details

The clinical study involves SAR448272/NX-3911, which is designated as an oral STAT6 degrader. Sanofi, acting as the collaborator, initiated the Phase 1 first-in-human clinical trial. This phase is designed to assess the initial safety profile and pharmacokinetics of the new molecular entity in humans.

Collaboration Context

The agreement between Nurix Therapeutics and Sanofi includes milestone payments tied to specific clinical development achievements. The recent payment reflects the successful transition of SAR448272/NX-3911 into the clinical stage under Sanofi's execution. As a focused biopharmaceutical firm, Nurix leverages such partnerships to advance its portfolio of targeted protein degradation medicines toward potential commercialization.

What the Numbers Show

The $10 million milestone payment provides immediate liquidity to Nurix Therapeutics, supporting its ongoing operations and research efforts. The achievement highlights the viability of the oral STAT6 degrader platform, moving it beyond preclinical stages into human testing. For investors, this marks a de-risking event for the asset, validating the collaborative framework with Sanofi and confirming progress on the agreed-upon development timeline.

Nurix Therapeutics, Inc. (NASDAQ: NRIX) has enrolled the first patient in the global Phase 3 DAYBreak CLL-306 study, marking a pivotal milestone for its lead candidate bexobrutideg. Conducted under a collaboration with Roche, the registrational trial evaluates bexobrutideg, a targeted protein degrader of Bruton’s tyrosine kinase (BTK), against pirtobrutinib, the current standard of care, in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This head-to-head comparison seeks to redefine treatment outcomes for patients whose disease progressed following prior covalent BTK inhibitor therapy.

The randomized Phase 3 trial is designed to enroll approximately 620 patients globally. Participants will be randomized on a 1:1 basis to receive either bexobrutideg 600 mg orally once per day or pirtobrutinib. The dual primary endpoints are objective response rate (ORR) and progression-free survival (PFS), assessed by an independent review committee. The study is structured to support global regulatory submissions by demonstrating the potential superiority of bexobrutideg relative to the non-covalent BTK inhibitor.

Clinical Development Strategy

Bexobrutideg (NX-5948) is an investigational, orally bioavailable, brain-penetrant, and highly selective small-molecule degrader of BTK. Nurix is advancing a broad clinical development program across oncology, immunology, and neurology. In addition to DAYBreak CLL-306, the pipeline includes:

Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, stated that targeted protein degradation offers a fundamentally differentiated approach compared to traditional small molecule inhibition. He emphasized that the trial is designed to test whether this differentiation translates into superior patient outcomes. Paula O’Connor, M.D., chief medical officer, noted that bexobrutideg has demonstrated robust clinical activity with a favorable safety and tolerability profile in relapsed/refractory CLL settings.

What the Numbers Show

The design of DAYBreak CLL-306 highlights a strategic shift toward direct comparative efficacy data. By selecting pirtobrutinib as the comparator, Nurix is challenging the existing non-covalent BTK inhibition standard rather than relying on historical controls or placebo arms. With a target enrollment of approximately 620 patients, the study size suggests sufficient statistical power to detect meaningful differences in ORR and PFS. This approach addresses significant unmet medical needs in patients who have failed covalent BTK inhibitors, positioning bexobrutideg as a potential best-in-class therapy if superiority is demonstrated.